GT
CRSP icon

Glenmede Trust’s CRISPR Therapeutics CRSP Stock Holding History

Glenmede Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,811
Closed -$379K – 1295
2022
Q3 		$379K Buy
+5,811
New +$421K ﹤0.01% 884
2022
Q2 		– Sell
-3,966
Closed -$248K – 1309
2022
Q1 		$248K Buy
+3,966
New +$249K ﹤0.01% 1083
2021
Q4 		– Sell
-2,441
Closed -$272K – 1335
2021
Q3 		$272K Hold
2,441
– – ﹤0.01% 1054
2021
Q2 		$394K Sell
2,441
-22
-0.9% -$2.68K ﹤0.01% 950
2021
Q1 		$299K Buy
2,463
+7
+0.3% +$1.06K ﹤0.01% 973
2020
Q4 		$375K Buy
2,456
+936
+62% +$111K ﹤0.01% 912
2020
Q3 		$126K Sell
1,520
-1,800
-54% -$160K ﹤0.01% 1111
2020
Q2 		$243K Buy
3,320
+770
+30% +$45K ﹤0.01% 964
2020
Q1 		$154K Hold
2,550
– – ﹤0.01% 1284
2019
Q4 		$154K Sell
2,550
-350
-12% -$19.1K ﹤0.01% 1284
2019
Q3 		$118 Sell
2,900
-3,110
-52% -$149K ﹤0.01% 1347
2019
Q2 		$282 Buy
6,010
+4,210
+234% +$168K ﹤0.01% 1062
2019
Q1 		$64 Hold
1,800
– – ﹤0.01% 1572
2018
Q4 		$51 Buy
+1,800
New +$62.6K ﹤0.01% 1578
2018
Q3 		– Sell
-2,349
Closed -$138K – 1522
2018
Q2 		$138K Buy
+2,349
New +$134K ﹤0.01% 1168

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Glenmede Trust's CRSP Position: Q4 2022 in Review

Glenmede Trust sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 5,811 shares — an estimated $379K sold.

Glenmede Trust first reported a position in CRSP in Q2 2018 and held it in 15 quarters. The position peaked at $394K in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Glenmede Trust reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Glenmede Trust sold 5,811 CRISPR Therapeutics shares in Q4 2022, an estimated $379K.
  • Glenmede Trust first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 15 quarters.
  • Glenmede Trust's CRISPR Therapeutics position peaked at $394K in Q2 2021.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.